Ulcerative Colitis (ABI-M201-101)

A randomized, double-blind, placebo-controlled, multi-center Phase 1b study to evaluate the safety, efficacy and microbiological response of orally administered ABI-M201 in subjects with mildly-to-moderately active Ulcerative Colitis with ongoing Mesalamine treatment. Register Today!

Atopic Dermatitis (B7451050)

A phase 3B randomized, double-blind, double-dummy, active controlled multi-center study assessing the efficacy and safety of Abrocitinib compared with Dupilumab in adult participants on background topical therapy with moderate to severe atopic dermatitis. Register Today!.